Developing novel medicines for serious immune system disorders
Recent News
Zura Bio to Present at Three Upcoming Investor Conferences in September
September 3, 2024
At Zura Bio, our mission is centered on enhancing the well-being of patients living with severe autoimmune and inflammatory conditions by developing novel medicines to dramatically improve their lives.
Our approach focuses on dual-pathway biology, signifying a potential paradigm shift for patients who currently find their needs underserved by single-pathway medicines. We aim to showcase the unique benefits of our portfolio, striving to meet the distinct needs of our therapeutic areas and make a tangible difference in patients’ well-being.
About Zura Bio
Zura Bio is led by a team of biotechnology entrepreneurs and pharmaceutical industry professionals with a proven track record of successfully identifying and developing innovative medicines that advance patient care and improve their well-being.
Pipeline
We are currently developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience.
Investors
Find our latest news, events, presentations, and financial updates.
Nasdaq Ticker: ZURA